![]() | ![]() |
Formats:
|
||||||||||||||||||||||||||||||||||||||||||||
Copyright : © 2005 Mayer-Scholl et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Human Neutrophils Kill Bacillus anthracis 1 Department of Cellular Microbiology, Max-Planck-Institute for Infection Biology, Berlin, Germany 2 Biochemistry Core Facility, Max-Planck-Institute for Infection Biology, Berlin, Germany 3 Microscopy Core Facility, Max-Planck-Institute for Infection Biology, Berlin, Germany 4 Protein Analysis Core Facilities, Max-Planck-Institute for Infection Biology, Berlin. Germany 5 Department of Microbiology, New York University School of Medicine, New York, New York, United States of America John Young, Editor The Salk Institute for Biological Studies, United States of America * To whom correspondence should be addressed. E-mail: zychlinsky/at/mpiib-berlin.mpg.de Received April 4, 2005; Accepted October 3, 2005. This article has been cited by other articles in PMC.Abstract Bacillus anthracis spores cause natural infections and are used as biological weapons. Inhalation infection with B. anthracis, the etiological agent of anthrax, is almost always lethal, yet cutaneous infections usually remain localized and resolve spontaneously. Neutrophils are typically recruited to cutaneous but seldom to other forms of anthrax infections, raising the possibility that neutrophils kill B. anthracis. In this study we infected human neutrophils with either spores or vegetative bacteria of a wild-type strain, or strains, expressing only one of the two major virulence factors. The human neutrophils engulfed B. anthracis spores, which germinated intracellularly and were then efficiently killed. Interestingly, neutrophil killing was independent of reactive oxygen species production. We fractionated a human neutrophil granule extract by high-performance liquid chromatography and identified α-defensins as the component responsible for B. anthracis killing. These data suggest that the timely recruitment of neutrophils can control cutaneous infections and possibly other forms of B. anthracis infections, and that α-defensins play an important role in the potent anti-B. anthracis activity of neutrophils. Synopsis Bacillus anthracis is the bacterium that causes anthrax, a disease that can occur through natural infections and also through intentional release. B. anthracis makes spores, which are in a dormant state, similar to seeds of a plant, and are extremely resistant to the environment. B. anthracis spores can infect through the skin or the lung. Lung infections disseminate through the body and are lethal. In contrast, skin infections often remain localized, and patients survive even without treatment. It is not well understood why these bacteria cause a localized infection through the skin and a lethal disease through the lung. Little is known about how B. anthracis is controlled. Neutrophils are the first white blood cells recruited to a site of infection and are specialized in killing microbes. Previous studies show that neutrophils are abundant in the skin form, but not in the lung form of anthrax. The researchers report that human neutrophils can take up B. anthracis spores. Once inside, the spores germinate to form vegetative bacteria. The vegetative bacteria are extremely susceptible to neutrophil-killing mechanisms. The B. anthracis virulence factors (molecules that make bacteria cause diseases) manipulate other human cells but do not deter neutrophils. B. anthracis is indeed exquisitely sensitive to the neutrophil protein α-defensin. These data support a new model where B. anthracis skin, but not lung, infections are controlled by the antimicrobial activity of neutrophils. Introduction The Gram-positive bacterium Bacillus anthracis infects through intradermal inoculation, ingestion, or inhalation of spores. Spores are dormant forms of B. anthracis and are extremely resistant to environmental stress. In the current model of respiratory infections, the spores are first taken up by macrophages where they germinate and become vegetative bacteria [1]. Macrophages then transport the bacteria to the regional lymph nodes [2]. In these organs, the bacteria escape from the macrophage and spread through the lymphatics and blood stream causing massive septicemia. Vegetative B. anthracis express two essential virulence factors: the tripartite anthrax toxin and the poly-γ-D glutamic acid capsule [3]. The toxin-protective antigen binds to its specific receptor and translocates the edema and lethal factors into the cytosol [4]. Edema factor is an adenylate cyclase that causes tissue edema [5], whereas lethal factor is a metalloprotease that inactivates mitogen-activated protein kinase-kinase and provokes cell death [6]. Neutrophils are a vital component of the acute inflammatory response and play a key role in the resolution of microbial infections. They are terminally differentiated cells, incapable of cell division, and synthesize very low levels of RNA and protein. Neutrophils engulf microbes into a phagosome that fuses with intracellular granules to form a phagolysosome. In the phagolysosome the bacteria are killed through the interaction of reactive oxygen species (ROS) [7] and oxygen-independent mediators such as enzymes and antimicrobial peptides [8]. Antimicrobial peptides are predominantly cationic and are thought to permeabilize the bacterial membrane and lyse microbes [9]. Inhalation B. anthracis infections result in sepsis and death, while cutaneous anthrax almost always remains localized. Interestingly, in untreated cutaneous cases, neutrophils surround the necrotic, bacteria-containing tissue [10], whereas neutrophil infiltration is rarely seen in the lung during inhalation anthrax [11]. Although there are reports of pulmonary infiltration in B. anthracis infections [12], they were thought to be due to preexisting lesions [13,14]. Pigs and dogs also develop a cutaneous form when infected subcutaneously. This form is reminiscent of human cutaneous anthrax and is accompanied by massive neutrophil infiltrations [13]. Also, neutrophil recruitment is found in the lungs of pulmonary infected dogs and pigs that survive high infection doses [14]. Therefore, we hypothesized that neutrophils can kill B. anthracis. Results/Discussion Human Neutrophils Kill B.anthracis Spores Independent of Reactive Oxygen Species We tested wild-type B. anthracis and strains expressing only the toxin or the capsule. We incubated neutrophils with a wild-type strain at a multiplicity of infection (MOI) of 5:1 (spores: neutrophils) and measured bacterial viability at different times. Activated neutrophils killed 60% of spores after 3 h, and at 4 h only 30% of the spores survived. Similar results were obtained from infections with the toxin- or capsule-producing strains (Figure 1
Neutrophils kill microbes through oxygen-dependent and independent mechanisms. ROS are generated by the nicotinamide adenosine dinucleotide phosphate (NADPH) oxidase and are important in some bacterial infections. To determine the role of ROS in the killing of B. anthracis, we inactivated neutrophil NADPH oxidase with diphenyleneiodonium (DPI) [17] (Figure S1), and found that the antimicrobial activity was not dependent on ROS (Figure 1 B. anthracis Spores Germinate within Human Neutrophils Neutrophils were infected with spores, and the germination of B. anthracis in the cells was analyzed by transmission electron microscopy (TEM). At 90 min post-infection, newly germinated vegetative bacteria were observed for the first time (Figure 2
To confirm that germination occurred intracellularly, we prevented neutrophil phagocytosis by incubating activated neutrophils with cytochalasin D, an inhibitor of actin polymerization. Inhibition of phagocytosis completely abrogated the sporicidal activity of the neutrophils (Figure 2 Human Neutrophils Efficiently Kill Vegetative B. anthracis To determine whether vegetative B. anthracis are killed by neutrophils, we infected activated cells with the wild-type strain or with those expressing either the toxin or the capsule. Both the fully virulent and the toxin-expressing strains were phagocytosed despite the large size of the B. anthracis bacilli (~5 microns) (Figure 3
To determine if extracellular mechanisms are responsible for B. anthracis killing, we again inhibited neutrophil phagocytosis. In the presence of cytochalasin D, all three B. anthracis strains were killed equally well (Figure 3 Interestingly, opsonization did not significantly affect the rate of killing of either capsule- or toxin-expressing vegetative bacteria (Figure 4
Analogously to spore killing, vegetative B. anthracis are killed independent of ROS production (Figure 4 Neutrophils Kill B. anthracis through α-Defensins To identify the components of the hNGE responsible for B. anthracis killing, hNGE was fractionated by C4 reverse phase high-performance liquid chromatography (RP-HPLC). The peak fraction exhibiting antimicrobial activity in the first column (Figure 5
α-defensins are a group of small antimicrobial peptides found in human neutrophil granules [24]. The three major human α-defensins differ by one amino acid, and all kill bacteria [25] effectively, although some Gram-positive pathogens such as S. aureus are resistant [26]. To confirm that α-defensins are responsible for neutrophil killing of B. anthracis, we compared the antimicrobial activity of the purified fraction to synthetic human α-defensin (Figure 5 The data presented here show that human neutrophils engulf B. anthracis spores and induce them to germinate. Neutrophils then efficiently kill the bacteria independent of toxin or capsule expression. The timely recruitment of neutrophils to the site of a cutaneous anthrax infection could explain why these infections resolve spontaneously. In inhalation anthrax, where there is little neutrophil infiltration [11], the infection progresses unchecked and leads to sepsis and death. Here we also show that α-defensins play an important role in the potent anti-B. anthracis activity of neutrophils. Materials and Methods Human neutrophil isolation. Heparinized venous blood was obtained after informed consent of healthy volunteers. Neutrophils ( > 95% pure) were isolated using a dextran-sedimentation protocol followed by centrifugation in a Ficoll-Paque gradient [27]. Erythrocytes were lysed with ultra-pure water for 30 s and cells washed in HBSS- and diluted in RPMI/10 mM HEPES with or without 10% FCS. Bacterial strains. All experiments were performed using either the wild-type (Vollum), the capsule-producing (Pasteur), or toxin-producing (Sterne) B. anthracis strain and performed in a BSL-3 facility. The anthrax strains were a kind gift of W. Beyer, University of Hohenheim. For toxin expression, bacteria were grown on BHI agar plates with 0.8% sodium bicarbonate at 37 °C, 5% CO2. A single colony was subcultured overnight in the supplemented BHI. The wild-type strain was additionally incubated in 5% CO2 atmosphere. The capsule-producing strain was grown on BHI plates for 2 d at 37 °C and 20% CO2 and a single colony was subcultured overnight in RPMI supplemented with 10% BHI, 10 mM HEPES, and 0.8% sodium bicarbonate. Toxin and capsule production. Lethal and edema factors, as well as protective antigen expressions, were monitored by Western Blot analysis of TCA-precipitated bacterial culture supernatant using antibodies from Abcam (Abcam, Cambridge, United Kingdom); γ-D-glutamic acid capsule expression was examined by India ink stain. Preparation of B. anthracis endospore suspensions. Strains were grown in BHI overnight at 37 °C before plating on meat yeast agar and incubated for 10 d at 37 °C and 5% CO2. The spores were scraped off, washed five times with PBS, and kept in PBS at 4 °C until use. The wild-type strain spores were purified with Renografin as described by Ivins et al. [28]. They were washed four times with water and kept in water at 4 °C. Purity was confirmed by phase contrast microscopy and heat treatment (60 °C, 45 min). Antimicrobial activity of neutrophils. 2 × 106/ml neutrophils were allowed to adhere to plastic plates for 15 min before activation with 25 nM PMA Sigma (Sigma, St. Louis, Missouri, United States) or 10 ng/ml Il-8 (BioCat, Heidelberg, Germany) for 30 min. Bacterial suspensions (vegetative cells or spores) were centrifuged onto the neutrophils (1,250 rpm, 10 min) and incubated for the indicated time points at 37 °C. For opsinization experiments vegetative bacteria were preincubated for 10 min with 5% non-inactivated human serum. Killing experiments were performed in the presence of a final concentration of 5% human serum. The cells were scraped off and serial dilutions plated on BHI agar plates. Colonies were counted after 12-h incubation at 37 °C, 5% CO2. Bacterial killing was measured as percentages of control values (bacteria incubated alone in media without neutrophils). To measure antimicrobial activity in the absence of ROS, neutrophils were preincubated with 10 μM of the NADPH oxidase inhibitor DPI [17] for 30 min. Inhibition of the respiratory burst was confirmed by enhanced chemiluminescence of PMA (25 nM)-activated neutrophils [29]. The experiment was read in a BD Pharmagen TM, Monolight 3096 microplate luminometer (BD Biosciences Pharmingen, San Diego, California, United States). Inhibition of phagocytosis. Neutrophils were isolated as described above and allowed to adhere to plastic plates for 15 min. Cells were activated with PMA (25 ng/ml) for 30 min, spun down at 1,250 rpm for 5 min. The supernatant was discarded and media containing 10 μg/ml cytochalsin D (Sigma) was added for 15 min at 37 °C. Cells were infected with spores or vegetative bacteria as described above. To confirm that spores do not germinate in the presence of neutrophils, 25 μg/ml PenicillinG (Sigma-Aldrich) was added to the cytochalsin D- treated cells prior to infection. Chromatography. hNGE was fractionated with a C4 RP-HPLC column (Vydac Protein C4 Column, 3.9 × 250 mm, 5 μm). Proteins were eluted with a gradient of increasing concentrations of acetonitril containing 0.1% (v/v) trifluoroacetic acid (flow rate 1 ml/min). Fractions were lyophilized, dissolved in 20 mM of sodium acetate buffer and tested for antimicrobial activity. The antimicrobial activity was further purified in a second C4 column, (mobile phase 100 mM of ammonium acetate [pH5]), followed by a C18 RP-HPLC column (X-terra RP18, 3.9 × 150 mm, 3.5 μm) with an acetonitril and 0.1% (v/v) trifluoroacetic acid gradient (flow rate 1 ml/min). Separation was performed in a Waters 626 LC System with a Water 996 Photodiode Array Detector (Waters, Milford, Massachusetts, United States). Bactericidal activity. hNGE was prepared as described in [30]. The bactericidal activity of hNGE, HPLC fractions, or synthetic human α-defensin 2 (American Peptide Company, Sunnyvale, California, United States) was determined by incubation with bacteria (107 bacteria/ml) in a casamino buffer (0.3% casamino acids, HBSS-, 10 mM HEPES [pH7.4]) at 37 °C, with the indicated doses, shaking for 30 min. Antimicrobial activity of each hNGE batch was tested with the toxin- expressing B. anthracis strain. Survivors were counted in serial dilutions. Bacterial killing was measured as percentages of control values (bacteria incubated in media alone). Electron microscopy. For TEM, cells were fixed with 2.5% glutaraldehyde, post-fixed with 1% osmium tetroxide, contrasted with uranylacetate and tannic acid, and dehydrated and embedded in Spurr's (Ted Pella, Redding, California, United States). After polymerization, specimens were cut at 60 nm and contrasted with lead citrate. Specimens were analyzed in a Leo 906E TEM. For scanning electron microscopy: Cells were fixed with 2.5% glutaraldehyde, post-fixed using repeated incubations with 1% osmium tetroxide/1% tannic acid, dehydrated with a graded ethanol series, critical-point dried, and coated with 2 nm platinum. After dehydration and critical-point drying, the specimens were coated with 5 nm Platinum/Carbon and analyzed in a Leo 1550 scanning electron microscopy. Mass spectrometry. The identity and purity of the antimicrobial component was analyzed by MALDI mass spectrometry (Proteomics 4700 workstation, Applied Biosystems, Foster City, California, United States), PMF, MS/MS analysis, and mass analysis of the uncleaved protein. The lyophilized sample was digested with 50 mM NH4HCO3, 5% acetonitrile, 2% (w/v) trypsin (Sequencing grade modified Trypsin, Promega, Madison, Wisconsin, United States), and 0.15M DTT for 4 h at 37 °C. The reaction was stopped with 0.2% TFA and mixed with matrix alpha-Cyano-4-hydroxycinnamic acid (CHCA) solubilized in 50% acetonitrile 0.3% TFA with a concentration of 5 mg/ml. Analysis of PMFs was obtained with parameters: reflectron mode, 20 kV accelerating voltage, and a low mass gate of 800 Da. MS/MS spectra were obtained without collision gas. Parameters for database searches (MASCOT, http://www.matrixscience.com) were: 30 ppm peptide mass tolerance for PMF and 0.3 Da for MS/MS spectra. The uncleaved protein was analyzed in linear mode with CHCA as matrix with an internal marker (Mr 2465.21). Figure S1: Inhibition of Respiratory Burst by DPI PMA-(25 nM) activated neutrophils were incubated in the presence (□) or absence ( ) of DPI and chemiluminescence monitored in a BD Pharmagen TM, Monolight 3096 microplate luminometer in the presence of luminol.(782 KB TIF) Click here for additional data file.(782K, tif) Acknowledgments We thank Wolfgang Beyer from the University of Hohenheim for providing us with the B. anthracis strains and many helpful comments. We thank Ulrike Reichard and Beatrix Fauler for help with electron microscopy, as well as Wolfgang Höhenwarter for the LC/ESI/MS analysis. We thank Constance Scharff and members of the Department of Cellular Microbiology, Max-Planck-Institute for Infection Biology for helpful comments. YW is supported by the National Institutes of Health IH grant 1 R21 AI057579-01A1. Abbreviations
Footnotes Competing interests. The authors have declared that no competing interests exist. Author contributions. AMS, YW, and AZ conceived and designed the experiments. AMS, RH, VB, and MS performed the experiments. AMS, RH, VB, MS, and AZ analyzed the data. PJ contributed reagents/materials/analysis tools. AMS and AZ wrote the paper. Citation: Mayer-Scholl A, Hurwitz R, Brinkmann V, Schmid M, Jungblut P, et al. (2005) Human neutrophils kill Bacillus anthracis. PLoS Pathog 1(3): e23. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||||||||||||||||||||||||
Mol Microbiol. 1999 Jan; 31(1):9-17.
[Mol Microbiol. 1999]Curr Top Microbiol Immunol. 2002; 271():115-41.
[Curr Top Microbiol Immunol. 2002]Annu Rev Microbiol. 2001; 55():647-71.
[Annu Rev Microbiol. 2001]Nature. 2001 Nov 8; 414(6860):225-9.
[Nature. 2001]Proc Natl Acad Sci U S A. 1982 May; 79(10):3162-6.
[Proc Natl Acad Sci U S A. 1982]Blood. 1998 Nov 1; 92(9):3007-17.
[Blood. 1998]Blood. 1997 May 15; 89(10):3503-21.
[Blood. 1997]Curr Opin Immunol. 1999 Feb; 11(1):23-7.
[Curr Opin Immunol. 1999]Proc Natl Acad Sci U S A. 1993 Mar 15; 90(6):2291-4.
[Proc Natl Acad Sci U S A. 1993]Ann N Y Acad Sci. 1980; 353():83-93.
[Ann N Y Acad Sci. 1980]Science. 1994 Nov 18; 266(5188):1202-8.
[Science. 1994]J Comp Pathol. 1968 Oct; 78(4):445-8.
[J Comp Pathol. 1968]Microb Pathog. 1989 Jul; 7(1):15-35.
[Microb Pathog. 1989]Mol Microbiol. 1999 Jan; 31(1):9-17.
[Mol Microbiol. 1999]Infect Immun. 2002 Oct; 70(10):5870-2.
[Infect Immun. 2002]Biochem J. 1986 Jul 1; 237(1):111-6.
[Biochem J. 1986]Infect Immun. 1985 Jan; 47(1):306-10.
[Infect Immun. 1985]EMBO J. 2005 Jan 12; 24(1):221-7.
[EMBO J. 2005]Infect Immun. 1985 Jan; 47(1):306-10.
[Infect Immun. 1985]Br J Exp Pathol. 1963 Aug; 44():446-53.
[Br J Exp Pathol. 1963]Br J Exp Pathol. 1963 Aug; 44():446-53.
[Br J Exp Pathol. 1963]J Infect Dis. 2002 Jul 15; 186(2):227-33.
[J Infect Dis. 2002]Infection. 1994 Jul-Aug; 22(4):281-2.
[Infection. 1994]Infect Immun. 2003 Jan; 71(1):546-9.
[Infect Immun. 2003]Nat Rev Immunol. 2003 Sep; 3(9):710-20.
[Nat Rev Immunol. 2003]Pharmacol Ther. 1995 May; 66(2):191-205.
[Pharmacol Ther. 1995]Peptides. 2001 Oct; 22(10):1651-9.
[Peptides. 2001]Microb Pathog. 1989 Jul; 7(1):15-35.
[Microb Pathog. 1989]Scand J Clin Lab Invest Suppl. 1968; 97():77-89.
[Scand J Clin Lab Invest Suppl. 1968]J Immunol Methods. 1999 Dec 17; 232(1-2):3-14.
[J Immunol Methods. 1999]